NRAS and acute myeloid leukemia: Krauth et al. performed a comprehensive genetic analysis of 139 AML patients with RUNX1-RUNX1T1 and found that the most frequent coexisting mutations were KIT, followed by NRAS, ASXL1 FLT3-ITD, FLT3-TKD, CBL, and KRAS, and overall RAS pathway-activating mutations including NRAS, KRAS, FLT3-ITD, FLT3-TKD, CBL, and JAK2 were found in 30.9% [41].